References
- Sinclair R, Eisman S, Song W, et al. Incidence and prevalence of alopecia areata in the Australian primary care setting: a retrospective analysis of electronic health record data. Australas J Dermatol. 2023;64(3):330–338. doi: 10.1111/ajd.14126
- Cranwell WC, Lai VW, Photiou L, et al. Treatment of alopecia areata: an Australian expert consensus statement. Australas J Dermatol. 2019;60(2):163–170. doi: 10.1111/ajd.12941
- Lauron S, Plasse C, Vaysset M, et al. Prevalence and odds of depressive and anxiety disorders and symptoms in children and adults with Alopecia Areata: a systematic review and meta-analysis. JAMA Dermatol. 2023;159(3):281–288. doi: 10.1001/jamadermatol.2022.6085
- Wang LH, Ma SH, Tai YH, et al. Increased risk of suicide attempt in patients with Alopecia Areata: a nationwide population-based cohort study. Dermatology. 2023;239(5):712–719. doi: 10.1159/000530076
- Toussi A, Barton VR, Le ST, et al. Psychosocial and psychiatric comorbidities and health-related quality of life in alopecia areata: a systematic review. J Am Acad Dermatol. 2021;85(1):162–175. doi: 10.1016/j.jaad.2020.06.047
- King BA, Senna MM, Ohyama M, et al. Defining severity in Alopecia Areata: Current perspectives and a multidimensional framework. Dermatol Ther (Heidelb). 2022;12(4):825–834. doi: 10.1007/s13555-022-00711-3
- Lensing M, Jabbari A. An overview of JAK/STAT pathways and JAK inhibition in alopecia areata. Front Immunol. 2022;13:955035. doi: 10.3389/fimmu.2022.955035
- Ho CY, Wu CY, Chen JY, et al. Clinical and genetic aspects of Alopecia Areata: a cutting edge review. Genes (Basel). 2023;14(7):1362.
- Alhanshali L, Buontempo MG, Lo Sicco KI, et al. Alopecia Areata: burden of disease, approach to treatment, and current unmet needs. Clin Cosmet Investig Dermatol. 2023;16:803–820. doi: 10.2147/CCID.S376096
- King B, Ohyama M, Kwon O, et al. Two phase 3 trials of baricitinib for Alopecia Areata. N Engl J Med. 2022;386(18):1687–1699. doi: 10.1056/NEJMoa2110343.
- Kwon O, Senna MM, Sinclair R, et al. Efficacy and safety of Baricitinib in patients with severe Alopecia Areata over 52 weeks of continuous therapy in two phase III trials (BRAVE-AA1 and BRAVE-AA2). Am J Clin Dermatol. 2023;24(3):443–451. doi: 10.1007/s40257-023-00764-w
- King B, Zhang X, Harcha WG, et al. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial. Lancet. 2023;401(10387):1518–1529. doi: 10.1016/S0140-6736(23)00222-2.
- Sunpharma.com [Internet]. Late breaking phase 3 data at AAD 2023 show oral investigational medicine deuruxolitinib significantly improved scalp hair regrowth in Alopecia Areata. Mumbai (India): Sun Pharmaceutical Industries Limited; 2023 Mar 18 [cited 2023 Nov 1]. Available from: https://sunpharma.com/wp-content/uploads/2023/03/Press-Relaese-Late-Breaking-Phase-3-Data-at-AAD-2023-Show-Oral-Investigational-Medicine-Deuruxolitinib.pdf
- U.S Food and Drug Administration [Internet]. FDA approves first systemic treatment for Alopecia Areata. Silver Spring (MD): United States government; 2022 Jun 13 [cited 2023 Oct 23]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-systemic-treatment-alopecia-areata
- European Medicines Agency [Internet]. Amsterdam (NL): European Medicines Agency c1995-2023. Olumiant (baricitinib); 2020 Oct 27 [cited 2023 Oct 23]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/olumiant#authorisation-details-section
- Therapeutic Goods Administration [Internet]. Olumiant (Eli Lilly Australia Pty Ltd). Canberra (ACT): Australian Government Department of Health and Aged Care; 2023 May 15 [cited 2023 Oct 23]. Available from: https://www.tga.gov.au/resources/prescription-medicines-registrations/olumiant-eli-lilly-australia-pty-ltd-1
- King B, Shapiro J, Ohyama M, et al. When to expect scalp hair regrowth during treatment of severe alopecia areata with baricitinib: insights from trajectories analyses of patients enrolled in two phase III trials. Br J Dermatol; 2023 Sep 14 [cited 2023 Nov 7];189(6):666–673. doi: 10.1093/bjd/ljad253
- clinicaltrials.gov. A study of baricitinib (LY3009104) in children from 6 years to less than 18 years of age with Alopecia Areata (BRAVE-AA-PEDS). Bethesda (MD): National Library of Medicine; 2023 Feb 10 [cited 2023 Nov 2]. Available from: https://clinicaltrials.gov/study/NCT05723198
- pfizer.com. FDA approves Pfizer’s LITFULO™ (ritlecitinib) for adults and adolescents with severe Alopecia Areata. (NY) (NY): Pfizer, Inc; 2023 Jun 23 [cited 2023 Oct 30]. Available from: https://www.pfizer.com/news/press-release/press-release-detail/fda-approves-pfizers-litfulotm-ritlecitinib-adults-and
- European Medicines Agency [Internet]. Amsterdam (NL): European Medicines Agency c1995-2023 litfulo (ritlecitinib); 2023 Sep 18 [cited 2023 Oct 23]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/litfulo
- Ramírez-Marín HA, Tosti A. Evaluating the therapeutic potential of ritlecitinib for the treatment of Alopecia Areata. Drug Des Devel Ther. 2022;16:363–374. doi: 10.2147/DDDT.S334727
- Guttman-Yassky E, Pavel AB, Diaz A, et al. Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers. J Allergy Clin Immunol. 2022;149(4):1318–1328. doi: 10.1016/j.jaci.2021.10.036
- King B, Guttman-Yassky E, Peeva E, et al. A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results. J Am Acad Dermatol. 2021;85(2):379–387. doi: 10.1016/j.jaad.2021.03.050
- Craiglow BG, King BA. Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis. J Invest Dermatol. 2014;134(12):2988–2990. doi: 10.1038/jid.2014.260
- Guo L, Feng S, Sun B, et al. Benefit and risk profile of tofacitinib for the treatment of alopecia areata: a systemic review and meta-analysis. J Eur Acad Dermatol Venereol. 2020;34(1):192–201. doi: 10.1111/jdv.15937
- Lai VWY, Bokhari L, Sinclair R. Sublingual tofacitinib for alopecia areata: a roll-over pilot clinical trial and analysis of pharmacokinetics. Int J Dermatol. 2021;60(9):1135–1139. doi: 10.1111/ijd.15657
- Almutairi N, Nour TM, Hussain NH. Janus kinase inhibitors for the treatment of severe Alopecia Areata: an open-label comparative study. Dermatology. 2019;235(2):130–136. doi: 10.1159/000494613
- Mackay-Wiggan J, Jabbari A, Nguyen N, et al. Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata. JCI Insight. 2016;1(15):e89790. doi: 10.1172/jci.insight.89790
- Liu LY, King BA. Ruxolitinib for the treatment of severe alopecia areata. J Am Acad Dermatol. 2019;80(2):566–568. doi: 10.1016/j.jaad.2018.08.040
- clinicaltrials.gov [Internet]. A study to evaluate efficacy and safety of deucravacitinib in participants with Alopecia Areata.Bethesda (MD): National Library of Medicine; 2022 Sep 23 [cited 2023 Oct 31]. Available from: https://clinicaltrials.gov/study/NCT05556265?intr=Deucravacitinib&cond=Alopecia%20Areata&rank=1
- clinicaltrials.gov [Internet]. A study to evaluate the safety and effectiveness of upadacitinib tablets in adult and adolescent participants with severe Alopecia Areata (up-AA). Bethesda (MD): National Library of Medicine; 2023 Aug 22 [cited 2023 Oct 28]. Available from: https://clinicaltrials.gov/study/NCT06012240?cond=Alopecia%20Areata&intr=Upadacitinib&rank=1
- AbbVie News Centre [Internet]. RINVOQ® (upadacitinib) receives its sixth U.S. FDA approval. North Chicago (IL): AbbVie Inc; 2022 Oct 21 [cited 2023 Oct 28]. Available from: https://news.abbvie.com/news/press-releases/rinvoq-upadacitinib-receives-its-sixth-us-fda-approval.htm
- European Medicines Agency. Amsterdam (NL): European Medicines Agency c1995-2023. Rinvoq (upadacitinib); 2019 Dec 18 [cited 2023 Oct 31]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/rinvoq
- Flora A, Kozera E, Frew JW. Treatment of alopecia areata with the janus kinase inhibitor upadacitinib: a retrospective cohort study. J Am Acad Dermatol. 2023;89(1):137–138. doi: 10.1016/j.jaad.2022.12.056
- Chiricozzi A, Balato A, Fabbrocini G, et al. Beneficial effects of upadacitinib on alopecia areata associated with atopic dermatitis: a multicenter retrospective study. J Am Acad Dermatol. 2023;89(6):1251–1253. doi: 10.1016/j.jaad.2023.05.001
- clinicaltrials.gov [Internet]. Study to evaluate the safety and efficacy of Jaktinib in adults with Alopecia Areata (AA). Bethesda (MD): National Library of Medicine; 2021 Nov 20 [cited 2023 Oct 29]. Available from: https://clinicaltrials.gov/study/NCT05051761?term=ZGJAK018&rank=2
- Zhou C, Yang X, Yang B, et al. A randomized, double-blind, placebo-controlled phase II study to evaluate the efficacy and safety of ivarmacitinib (SHR0302) in adult patients with moderate-to-severe alopecia areata. J Am Acad Dermatol. 2023;89(5):911–919. doi: 10.1016/j.jaad.2023.02.063
- Olsen EA, Kornacki D, Sun K, et al. Ruxolitinib cream for the treatment of patients with alopecia areata: a 2-part, double-blind, randomized, vehicle-controlled phase 2 study. J Am Acad Dermatol. 2020;82(2):412–419. doi: 10.1016/j.jaad.2019.10.016
- Mikhaylov D, Glickman JW, Del Duca E, et al. A phase 2a randomized vehicle-controlled multi-center study of the safety and efficacy of delgocitinib in subjects with moderate-to-severe alopecia areata. Arch Dermatol Res. 2023;315(2):181–189.
- Liu LY, Craiglow BG, King BA. Tofacitinib 2% ointment, a topical janus kinase inhibitor, for the treatment of alopecia areata: a pilot study of 10 patients. J Am Acad Dermatol. 2018;78(2):403–404.e1. doi: 10.1016/j.jaad.2017.10.043
- Song T, Pavel AB, Wen HC, et al. An integrated model of alopecia areata biomarkers highlights both TH1 and TH2 upregulation. J Allergy Clin Immunol. 2018;142(5):1631–1634.e13. doi: 10.1016/j.jaci.2018.06.029
- Beaziz J, Bouaziz JD, Jachiet M, et al. Dupilumab-induced psoriasis and alopecia areata: case report and review of the literature. Ann Dermatol Venereol. 2021;148(3):198–201.
- Carnicle JM, Hendricks AJ, Shi VY. Reactivation of Alopecia Areata after dupilumab therapy for atopic dermatitis. Dermatitis. 2021;32(1S):e80–e82. doi: 10.1097/DER.0000000000000512
- Flanagan K, Sperling L, Lin J. Drug-induced alopecia after dupilumab therapy. JAAD Case Rep. 2018;5(1):54–56. doi: 10.1016/j.jdcr.2018.10.010
- Chung J, Slaught CL, Simpson EL. Alopecia areata in 2 patients treated with dupilumab: new onset and worsening. JAAD Case Rep. 2019;5(8):643–645. doi: 10.1016/j.jdcr.2019.03.019
- Guttman-Yassky E, Renert-Yuval Y, Bares J, et al. Phase 2a randomized clinical trial of dupilumab (anti-IL-4Rα) for alopecia areata patients. Allergy. 2022;77(3):897–906. doi: 10.1111/all.15071
- Ramot Y, Marzani B, Pinto D, et al. IL-17 inhibition: is it the long-awaited savior for alopecia areata? Arch Dermatol Res. 2018;310(5):383–390. doi: 10.1007/s00403-018-1823-y
- Guttman-Yassky E, Nia JK, Hashim PW, et al. Efficacy and safety of secukinumab treatment in adults with extensive alopecia areata. Arch Dermatol Res. 2018;310(8):607–614. doi: 10.1007/s00403-018-1853-5
- Le Duff F, Bouaziz JD, Fontas E, et al. Low-dose IL-2 for treating moderate to severe Alopecia Areata: a 52-week multicenter prospective placebo-controlled study assessing its impact on T regulatory cell and NK cell populations. J Invest Dermatol. 2021;141(4):933–936.e6.
- Tavoletti G, Chiei-Gallo A, Barei F, et al. Tralokinumab as a therapeutic option for patients with concurrent atopic dermatitis and alopecia areata. Int J Dermatol. 2024;63(3):374–375. doi: 10.1111/ijd.17010
- clinicaltrials.gov. Study of Daxdilimab for the treatment of moderate-to-severe Alopecia Areata. Bethesda (MD): National Library of Medicine; 2022 Apr 11 [cited 2023 Oct 29]. Available from: https://clinicaltrials.gov/study/NCT05368103?intr=daxdilimab&rank=2
- clinicaltrials.gov. A study to evaluate the efficacy and safety of Rosnilimab (ANB030) in treatment of subjects with moderate-to-severe Alopecia Areata (AZURE). Bethesda (MD): National Library of Medicine; 2022 Jan 11 [cited 2023 Oct 28]. Available from: https://clinicaltrials.gov/study/NCT05205070?cond=Alopecia%20Areata&intr=Rosnilimab&rank=1
- clinicaltrials.gov. Safety and efficacy of oral etrasimod in adult participants with moderate-to-severe Alopecia Areata. Bethesda (MD): National Library of Medicine; 2020 Sep 15 [cited 2023 Oct 28]. Available from: https://clinicaltrials.gov/study/NCT04556734?cond=Alopecia%20Areata&intr=etrasimod&rank=1
- clinicaltrials.gov. Study of EQ101 in adult subjects with moderate to severe Alopecia Areata. Bethesda (MD): National Library of Medicine; 2022 Oct 13 [cited 2023 Oct 30]. Available from: https://clinicaltrials.gov/study/NCT05589610?cond=Alopecia%20Areata&intr=EQ101&rank=1
- clinicaltrials.gov. Randomized, double-blind, placebo-controlled phase 2a, proof-of-concept trial of ADX-914 phase 2a trial for the treatment of severe Alopecia Areata (SIGNAL-AA). Bethesda (MD): National Library of Medicine; 2023 Aug 15 [cited 2023 Oct 29]. Available from: https://clinicaltrials.gov/study/NCT06018428?cond=Alopecia%20Areata&intr=ADX-914&rank=1
- Estébanez A, Estébanez N, Martín JM, et al. Apremilast in refractory Alopecia Areata. Int J Trichology. 2019;11(5):213–215. doi: 10.4103/ijt.ijt_59_19
- Weber B, Radakovic S, Tanew A. Apremilast for extensive and treatment-resistant alopecia areata: a retrospective analysis of five patients. Eur J Dermatol; 2020 [cited 2023 Oct 24];30(2):165–168. doi: 10.1684/ejd.2020.3749
- Liu LY, King BA. Lack of efficacy of apremilast in 9 patients with severe alopecia areata. J Am Acad Dermatol. 2017;77(4):773–774. doi: 10.1016/j.jaad.2017.05.034
- Mikhaylov D, Pavel A, Yao C, et al. A randomized placebo-controlled single-center pilot study of the safety and efficacy of apremilast in subjects with moderate-to-severe alopecia areata. Arch Dermatol Res. 2019;311(1):29–36. doi: 10.1007/s00403-018-1876-y
- Phan K, Sebaratnam DF. JAK inhibitors for alopecia areata: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2019;33(5):850–856. doi: 10.1111/jdv.15489
- Martinez J, Manjaly C, Manjaly P, et al. Janus Kinase Inhibitors and adverse events of acne: a systematic review and meta-analysis.JAMA Dermatol. 2023 [cited 2023 Nov 10];159(12):e233830. doi: 10.1001/jamadermatol.2023.3830
- Peterson D, Powell M, King B. Less is more? Failure of one JAK inhibitor does not predict failure of another one in a patient with alopecia areata. Dermatol Ther. 2021;34(5):e15062. doi: 10.1111/dth.15062
- Kazmi A, Moussa A, Bokhari L, et al. Switching between tofacitinib and baricitinib in alopecia areata: a review of clinical response. J Am Acad Dermatol. 2023;89(6):1248–1250. doi: 10.1016/j.jaad.2023.03.041
- Wambier CG, Craiglow BG, King BA. Combination tofacitinib and oral minoxidil treatment for severe alopecia areata. J Am Acad Dermatol. 2021;85(3):743–745. doi: 10.1016/j.jaad.2019.08.080
- Dincer D, Tanacan E, Kose Ozkan C. Efficacy of systemic minoxidil and tofacitinib combination in treatment-resistant alopecia universalis. J Cosmet Dermatol. 2021;20(6):1807–1809. doi: 10.1111/jocd.13812
- Wambier CG, Craiglow BG, King BA. Tratamento adjuvante com minoxidil oral para tratamento de alopecia areata refratária a inibidores de JAK. Surg Cosmet Dermatol. 2020;12(1):74–75. doi: 10.5935/scd1984-8773.20201211512
- Meznerics F, Illés K, Dembrovszky F, et al. Platelet-rich plasma in Alopecia Areata—A steroid-free treatment modality: a systematic review and meta-analysis of randomized clinical trials. Biomedicines. 2022;10(8):1829. doi: 10.3390/biomedicines10081829
- U.S Food and Drug Administration. Janus kinase (JAK) inhibitors: drug safety communication - FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death. Silver Spring (MD): United States government; 2021 Sep 1 [cited 2023 Oct 25]. Available from: https://www.fda.gov/safety/medical-product-safety-information/janus-kinase-jak-inhibitors-drug-safety-communication-fda-requires-warnings-about-increased-risk
- Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and cancer risk with tofacitinib in Rheumatoid Arthritis. N Engl J Med. 2022;386(4):316–326. doi: 10.1056/NEJMoa2109927
- Yoon S, Kim K, Shin K, et al. The safety of systemic janus kinase inhibitors in atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials. J Eur Acad Dermatol Venereol. 2024;38(1):52–61. doi: 10.1111/jdv.19426
- Liu M, Gao Y, Yang K, et al. Janus kinase inhibitors for Alopecia Areata: a systematic review and meta-analysis. JAMA Netw Open. 2023 [cited 2024 Feb 10];6(6):14. doi: 10.1001/jamanetworkopen.2023.20351
- Samuel C, Cornman H, Kambala A, et al. A review on the safety of using JAK inhibitors in dermatology: clinical and laboratory monitoring. Dermatol Ther (Heidelb). 2023;13(3):729–749. doi: 10.1007/s13555-023-00892-5